Table 3.
Comparison of Subjects With and Without Intermittent Low-level Viremia
| iLLV | Others | P Value | |
|---|---|---|---|
| (n = 374) | (n = 1632) | ||
| Malea | 354 (94.7) | 1518 (93.0) | .27 |
| Racea | .004 | ||
| White | 170 (45.5) | 663 (40.6) | |
| Black | 124 (33.2) | 691 (42.3) | |
| Hispanic/other | 80 (21.4) | 278 (17.0) | |
| Age at HIV diagnosis (years)b | 31.0 (25.5–37.6) | 29.0 (24.4–35.9) | .003 |
| HIV diagnosis eraa | .17 | ||
| Prior to 1996 | 71 (19.0) | 380 (23.3) | |
| 1996–2000 | 51 (13.6) | 227 (13.9) | |
| After 2000 | 252 (67.4) | 1025 (62.8) | |
| Time from HIV diagnosis to ART initiation (years)b | 0.7 (0.2–3.3) | 0.8 (0.2–3.8) | .68 |
| Initial ART regimena | <.0001 | ||
| Unboosted PI | 76 (20.3) | 399 (24.4) | |
| Boosted PI | 51 (13.6) | 157 (9.6) | |
| NNRTI | 204 (54.5) | 776 (47.5) | |
| INSTI | 15 (4.0) | 205 (12.6) | |
| Other | 28 (7.5) | 95 (5.8) | |
| Antiretroviral use prior to ARTa | 55 (14.7) | 353 (21.6) | .003 |
| CD4 count at HIV diagnosisb,c | 434.5 (298.0–610.0) | 459.5 (336.0–604.0) | .05 |
| CD4 count at ART initiationb,c | 344.0 (245.0–464.0) | 378.0 (276.0–507.0) | <.001 |
| Nadir CD4 countb | 301.5 (228.0–392.0) | 328.0 (243.0–436.0) | .001 |
| Log viral load at ART initiation (copies/mL)b,c | 4.7 (4.1–5.0) | 4.5 (3.8–4.9) | <.0001 |
| Follow-up time after HIV diagnosis (years)b | 10.5 (6.7–16.4) | 7.2 (3.6–13.2) | <.0001 |
| Follow-up time after ART initiation (years)b | 8.3 (5.5–13.7) | 4.7 (2.6–8.2) | <.0001 |
| Number of VL measurements/yearb | 2.0 (2.0–2.5) | 2.0 (1.5–2.0) | <.0001 |
| Number of VL measurements/subject with a LoQ of ≤50 copies/mLb | 17.0 (11.0–25.0) | 7.0 (4.0–14.0) | <.0001 |
| Number of VL measurements/subject with any LoQb | 18.0 (11.0–28.0) | 11.0 (6.0–22.0) | <.0001 |
P values were calculated by Kruskal-Wallis test and χ2/Fisher exact test for continuous and categorical variables, respectively.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; LoQ, limit of quantification; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; VL, viral load.
an (%).
bMedian (1st quartile to 3rd quartile).
cSubjects with missing values were not included in the computation of percentages and statistics.